Pharmafile Logo

News and Press Releases

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...

Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024

Exonate
info@exonate.com
WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom